The findings by Cruz et al.1 regarding the pervasive nature of leprosy-related stigma in Brazil are more than a psychosocial observation; they reveal a critical blind spot in epidemiological surveillance. Their study showed that stigma persists among patients, contacts, and the general population, with shame, negative self-opinion, and social avoidance emerging as central elements across groups. These findings suggest that stigma may interfere with early consultation, disclosure, contact tracing, and treatment adherence.

Current technical guidance, such as the recent practical review by Fróes Júnior et al.,2 provides valuable frameworks for clinical and laboratory diagnosis, including histopathology, RLEP-PCR, anti-PGL-1 serology, monofilament testing, and ultrasonography. However, even the most accurate diagnostic tools may have limited public health impact when affected individuals delay or avoid care because of fear, shame, or anticipated discrimination.

We therefore propose the concept of a stigma-induced diagnostic gap: the distance between diagnostic capacity and real-world access to diagnosis created by social concealment and avoidance. In endemic regions, stigma may contribute to hidden prevalence by keeping symptomatic individuals outside the reach of early detection and by weakening contact surveillance.

“Zero stigma” should not be regarded only as an aspirational target for 2030 but as a clinical and programmatic requirement today.3 Dermatology services in endemic areas should consider incorporating validated stigma screening tools into routine leprosy care, alongside neurological assessment, disability grading, and bacteriological evaluation.

If leprosy programs continue to treat M. leprae while underestimating social isolation, elimination efforts will remain incomplete. Closing the stigma-induced diagnostic gap is essential to transform biomedical cure into true public health control.